These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34253578)

  • 1. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial.
    Bockorny B; Macarulla T; Semenisty V; Borazanci E; Feliu J; Ponz-Sarvise M; Abad DG; Oberstein P; Alistar A; Muñoz A; Geva R; Guillén-Ponce C; Fernandez MS; Peled A; Chaney M; Gliko-Kabir I; Shemesh-Darvish L; Ickowicz D; Sorani E; Kadosh S; Vainstein-Haras A; Hidalgo M
    Clin Cancer Res; 2021 Sep; 27(18):5020-5027. PubMed ID: 34253578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.
    Bockorny B; Semenisty V; Macarulla T; Borazanci E; Wolpin BM; Stemmer SM; Golan T; Geva R; Borad MJ; Pedersen KS; Park JO; Ramirez RA; Abad DG; Feliu J; Muñoz A; Ponz-Sarvise M; Peled A; Lustig TM; Bohana-Kashtan O; Shaw SM; Sorani E; Chaney M; Kadosh S; Vainstein Haras A; Von Hoff DD; Hidalgo M
    Nat Med; 2020 Jun; 26(6):878-885. PubMed ID: 32451495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
    Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Ur Rehman SS; Lim K; Wang-Gillam A
    Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
    Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
    Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
    Cui J; Qin S; Zhou Y; Zhang S; Sun X; Zhang M; Cui J; Fang W; Gu K; Li Z; Wang J; Chen X; Yao J; Zhou J; Wang G; Bai Y; Xiao J; Qiu W; Wang B; Xia T; Wang C; Kong L; Yin J; Zhang T; Shen X; Fu D; Gao C; Wang H; Wang Q; Wang L
    Signal Transduct Target Ther; 2024 Sep; 9(1):248. PubMed ID: 39300077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
    Van Laethem JL; Borbath I; Prenen H; Geboes KP; Lambert A; Mitry E; Cassier PA; Blanc JF; Pilla L; Batlle JF; Garrote MR; Pazo-Cid RA; Gallego I; Smith KE; Ellmark P; Pico de Coaña Y; Ambarkhane SV; Macarulla T
    Lancet Oncol; 2024 Jul; 25(7):853-864. PubMed ID: 38834087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
    Kodama T; Imajima T; Shimokawa M; Otsuka T; Kawahira M; Nakazawa J; Hori T; Shibuki T; Arima S; Ido A; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Sakai K; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 May; 14(1):12422. PubMed ID: 38816500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
    Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
    Akahori T; Sho M; Yanagimoto H; Satoi S; Nagai M; Nishiwada S; Nakagawa K; Nakamura K; Yamamoto T; Hirooka S; Yamaki S; Ikeda N
    Oncologist; 2019 Jun; 24(6):749-e224. PubMed ID: 30679316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
    Yu HY; Lee CY; Lin LG; Chao Y; Li CP
    J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
    Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
    J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
    Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
    Mahalingam D; Wilkinson GA; Eng KH; Fields P; Raber P; Moseley JL; Cheetham K; Coffey M; Nuovo G; Kalinski P; Zhang B; Arora SP; Fountzilas C
    Clin Cancer Res; 2020 Jan; 26(1):71-81. PubMed ID: 31694832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.